Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the PPAR-γ modulator AGED can reverse epithelial-mesenchymal transition in hair follicles affected by lichen planopilaris ex vivo, suggesting potential for treating scarring alopecias.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This case report highlights a rare instance of erosive pustular dermatosis of the scalp in a patient on afatinib, underlining the importance of early recognition and management of this adverse effect.

This study found that patients with androgenetic alopecia experience significantly higher symptoms of anxiety, depression, stress, and body image dissatisfaction compared to non-AGA controls, along with generally reduced self-esteem and life satisfaction.

This review explores the link between androgenetic alopecia, advanced glycation end products, and RAGE, noting their potential role in exacerbating oxidative stress and inflammation related to hair follicle miniaturization.

In this animal study, researchers observed that ginsenoside CK significantly reduced hair loss, improved sexual organ health, and encouraged hair growth in mice with androgenetic alopecia by modulating key signaling pathways and normalizing hormone metabolism, highlighting its potential as a therapeutic agent.

This study found that nonablative Er:YAG laser therapy effectively improved hair appearance for patients with androgenetic alopecia, with most participants reporting increased satisfaction and no adverse reactions, following six biweekly sessions.

This study found that full-length Agouti protein modulates melanocortin receptor signaling through a dual mechanism involving competitive antagonism and receptor down-regulation, whereas the carboxyl-terminal fragment acts solely as a competitive antagonist.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

In this observational study, men with early onset androgenic alopecia exhibited a statistically significant correlation with more severe forms of coronary artery disease compared to those without the condition.

This study reported significant improvements in hair density and growth ratio in androgenetic alopecia patients receiving concentrated growth factor injections, with benefits sustained for 6 months.

In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.

This article reviews androgenetic alopecia, detailing its genetic and hormonal causes, clinical presentations, diagnosis, and treatment options, but it reports no new clinical findings.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

In this study, incorporating cetirizine into transferosome formulations significantly enhanced hair growth in mice and boosted IGF-1 and VEGF levels, suggesting that this method could be a promising alternative to traditional hair growth treatments, though further studies are needed to confirm its safety and suitability.

This study found a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting a need for celiac disease screening in these patients.

This study concluded that ACT injections, alone or combined with finasteride, have significant therapeutic effects and safety in treating androgenic alopecia, with promising clinical potential.

Stem cell therapies might help with hair loss, but more research is needed to confirm their safety and effectiveness.

A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.

AGA patients have a lower quality of life than AA patients.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This review discusses potential links between early-onset androgenetic alopecia and exposure to endocrine disruptors in adolescents, but reports no clinical results; the authors suggest further investigation.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This study found that while the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair and daily shed hair counts in AGA patients, it did not show significant differences compared to placebo in other measures.